Ceres Pharma NV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ceres Pharma NV - overview
Established
2015
Location
-, -, Belgium
Primary Industry
Pharmaceuticals
About
Based in Belgium, and formed by Alychlo in 2015, Ceres Pharma NV operates as a pharmaceutical company that engages in the development, production, and distribution of medical products, drugs, food supplements, and cosmetics intended for nutritherapy and phytotherapy in the Benelux and in Central and Eastern Europe. The company's CEO is Mario Debel. In July 2021, Naxicap Partners agreed to acquire 100% of the shares of Ceres Pharma NV from Alychlo. The company specializes in both over-the-counter (OTC) healthcare products and food supplements, and generic prescription drugs in the women’s health market.
Naxicap Partners will help Ceres Pharma NV to achieve internationalization and further expansion in the Benelux, Central Europe, and potentially beyond, and on the development of new sales channels and the scaling of the marketing activities.
Current Investors
Naxicap Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.ceres-pharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Ceres Pharma NV - timeline of key events
Ceres Pharma NV - financials
| Fiscal Year Ended | Mar 31, 2017 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | 26,813,238 | 30,358,783 | 33,093,842 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | 13.2% | 9.0% | - | - | - |
| EBITDA (USD) | (1,035,857) | (571,740) | (86,532) | 2,191,246 | 4,664,396 | 3,747,863 | - | - | - |
| Operating Income (USD) | (2,316,056) | (1,231,214) | (1,819,260) | (732,165) | 1,712,411 | 645,669 | - | - | - |
| Operating Margin | - | - | - | (2.7%) | 5.6% | 2.0% | - | - | - |
| % EBITDA Margin | - | - | - | 8.2% | 15.4% | 11.3% | - | - | - |
| NET Income (USD) | (3,315,687) | (2,005,633) | (3,734,811) | (3,535,396) | (1,087,097) | (2,591,903) | - | - | - |
| % Net Margin | - | - | - | (13.2%) | (3.6%) | (7.8%) | - | - | - |
Ceres Pharma NV - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out | Completed | Kela Pharma | - | ||||||||
| Add-on | Completed | Euronational S.r.l. | - | ||||||||
| Add-on | Completed | Amnol Chimica Biologica S.r.l. | - | ||||||||
| Secondary Buyout | Completed | Ceres Pharma NV | - | ||||||||
| Buyout | Completed | Ceres Pharma NV | - |
Displaying 1 - 5 of 5
Ceres Pharma NV - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.